In response to a recent proposal that would eliminate the United States Postal Service's Saturday mail delivery, the Pharmaceutical Care Management Association, which represents pharmacy benefit managers (PBMs) sent letters to Congress detailing the negative effect the reduction of deliveries would have on Americans relying on mail service pharmacies.
"About 1-in-6 prescriptions that are home delivered arrive on Saturday," says PCMA President and CEO Mark Merritt. "Consumers count on getting their prescriptions at the right time and often can't wait an additional two days, or even three days in the case of federal holidays that fall on a Monday."
Millions of Americans with chronic conditions rely on mail-service pharmacies for convenience and value, and PCMA argues that the elimination of Saturday delivery would be detrimental. A news release issued by PCMA details the findings of research conducted by government and independent studies to examine the increased savings and safety offered by mail-order pharmacies. Research highlights include:
The Postal Service's proposal (while noting that Saturday is its
lowest-volume delivery day) also mentions that the practice of delivering
mail to private retail locations is expanding, giving consumers more options for their own pickup. If Saturday delivery is stopped, PBMs can still rely on premium delivery services like FedEx and UPS, but likely at a premium price.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Racial, Social, and Economic Factors Drive Resilience During COVID-19 Pandemic, Study Finds
July 18th 2025The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.
Thermo Fisher, Sanofi Expand Partnership to Boost Sterile Drug Production
July 16th 2025Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.